包装
Navitoclax，ABT263是一种新的抗凋亡Bcl-2蛋白抑制剂，Ki＜1nM，也是一种新的抗癌药物。可溶于DMSO (100mg/ml at 25°C)和DMF (~30mg/ml)
Biochem/physiol Actions
Navitoclax is an orally bioavailable, synthetic small-molecule antagonist of a subset of the B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 selectively binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w and prevents their binding to the apoptotic effectors Bax and Bak proteins, which may trigger apoptosis in tumor cells overexpressing Bcl-2, Bcl-XL, and Bcl-w.
Navitoclax是B细胞白血病2（Bcl-2）家族蛋白的一个具有潜在抗肿瘤活性的口服生物合成小分子拮抗剂。 ABT-263选择性结合凋亡抑制蛋白Bcl-2，Bcl-XL和Bcl-w，并阻止它们与凋亡效应因子Bax和Bak蛋白结合，这可能会触发过表达Bcl-2，Bcl-XL， 和Bcl-w。
性质
| Purity | 99.0%，HPLC |
| Storage temp. | Keep in dark place,Sealed in dry,2-8 ℃ |
| Physical Form | solid |
| mp | 114-116 ℃ |
| Iupac Name | N-[4-(4-{[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl}-1-piperazinyl)benzoyl]-4-({(1R)-3-(4-morpholinyl)-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide |
| Inchi Code | 1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1 |
| Inchi Key | JLYAXFNOILIKPP-KXQOOQHDSA-N |
安全信息
个人防护装备 Eyeshields, Gloves, type N95 (US)
RIDADR NONH for all modes of transport
